Maven Securities LTD Boosts Stock Position in The Oncology Institute, Inc. $TOI

Maven Securities LTD grew its holdings in The Oncology Institute, Inc. (NASDAQ:TOI) by 151.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 251,128 shares of the company’s stock after buying an additional 151,128 shares during the quarter. Maven Securities LTD owned 0.26% of Oncology Institute worth $894,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in TOI. LPL Financial LLC increased its position in shares of Oncology Institute by 1.5% during the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock worth $964,000 after purchasing an additional 3,900 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Oncology Institute by 5.5% in the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock valued at $306,000 after purchasing an additional 4,489 shares during the last quarter. Cetera Investment Advisers lifted its stake in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after acquiring an additional 4,545 shares in the last quarter. Larson Financial Group LLC lifted its stake in Oncology Institute by 19.7% during the 4th quarter. Larson Financial Group LLC now owns 31,468 shares of the company’s stock worth $112,000 after acquiring an additional 5,181 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Oncology Institute by 141.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after purchasing an additional 7,091 shares during the period. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Oncology Institute

In related news, Director Mohit Kaushal sold 38,433 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $3.50, for a total value of $134,515.50. Following the transaction, the director owned 172,583 shares in the company, valued at approximately $604,040.50. The trade was a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Yale Podnos sold 23,451 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the completion of the transaction, the insider owned 259,527 shares in the company, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders purchased 250,500 shares of company stock valued at $870,795 and sold 119,170 shares valued at $461,183. Company insiders own 4.40% of the company’s stock.

Analysts Set New Price Targets

TOI has been the topic of a number of recent analyst reports. BTIG Research increased their price objective on Oncology Institute from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Oncology Institute in a report on Monday, March 9th. Finally, B. Riley Financial raised their price objective on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oncology Institute has a consensus rating of “Moderate Buy” and an average price target of $7.25.

Oncology Institute Trading Down 2.4%

Shares of Oncology Institute stock opened at $5.18 on Tuesday. The business’s fifty day moving average price is $4.03 and its 200 day moving average price is $3.47. The Oncology Institute, Inc. has a twelve month low of $2.02 and a twelve month high of $5.57. The stock has a market capitalization of $511.99 million, a P/E ratio of -14.00 and a beta of 0.37.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to analysts’ expectations of $142.10 million. As a group, sell-side analysts predict that The Oncology Institute, Inc. will post -0.17 EPS for the current year.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.